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Summary
Background.  —  The  transradial  approach  for  percutaneous  coronary  intervention  (PCI)  is  associ-
ated with  a  better  outcome  in  myocardial  infarction  (MI),  but  patients  with  cardiogenic  shock
(CS) were  excluded  from  most  trials.
Abbreviations: CI, conﬁdence interval; CS, cardiogenic shock; IABP, intra-aortic balloon pump; MI, myocardial infarction; PCI, percuta-
neous coronary intervention; RR, relative risk; TIMI, thrombolysis in myocardial infarction.
∗ Corresponding author.
E-mail address: beygui-f@chu-caen.fr (F. Beygui).
1 V.R. and A.L. participated equally in the work and are considered as co-ﬁrst authors.
http://dx.doi.org/10.1016/j.acvd.2015.06.005
1875-2136/© 2015 Elsevier Masson SAS. All rights reserved.
564  V.  Roule  et  al.
Death;
Major  bleeding
Aims.  —  To  compare  outcomes  of  PCI  for  MI-related  CS  via  the  transradial  versus  transfemoral
approach.
Methods.  —  A  prospective  cohort  of  101  consecutive  patients  admitted  for  PCI  for  MI-related
CS were  treated  via  the  transradial  (n  =  74)  or  transfemoral  (n  =  27)  approach.  Cox  propor-
tional hazards  models  adjusted  for  prespeciﬁed  variables  and  a  propensity  score  for  approach
were used  to  compare  mortality,  death/MI/stroke  and  bleeding  between  the  two  groups.  A
complementary  meta-analysis  of  six  studies  was  also  performed.
Results.  —  Patients  in  the  transradial  group  were  younger  (P  =  0.039),  more  often  male
(P =  0.002)  and  had  lower  GRACE  and  CRUSADE  scores  (P  =  0.003  and  0.001,  respectively)  and
rates of  cardiac  arrest  before  PCI  (P  =  0.009)  and  mechanical  ventilation  (P  =  0.006).  Rates  of  PCI
success were  similar.  At  a  mean  follow-up  of  756  days,  death  occurred  in  40  (54.1%)  patients  in
the transradial  group  versus  22  (81.5%)  in  the  transfemoral  group  (adjusted  hazard  ratio  [HR]:
0.49, 95%  conﬁdence  interval  [CI]  0.28—0.84;  P  =  0.012).  The  transradial  approach  was  asso-
ciated with  reduced  rates  of  death/MI/stroke  (adjusted  HR:  0.53,  95%CI:  0.31—0.91;  P  =  0.02)
and major  bleeding  (adjusted  HR:  0.34,  95%CI:  0.13—0.87;  P  =  0.02).  The  meta-analysis  con-
ﬁrmed the  beneﬁt  of  transradial  access  in  terms  of  mortality  (relative  risk  [RR]:  0.63,  95%CI:
0.58—0.68)  and  major  bleeding  (RR:  0.43,  95%CI:  0.32—0.59).
Conclusion.  —  The  transradial  approach  in  the  setting  of  PCI  for  ischaemic  CS  is  associated  with
a dramatic  reduction  in  mortality,  ischaemic  and  bleeding  events,  and  should  be  preferred  to
the transfemoral  approach  in  radial  expert  centres.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  L’accès  par  voie  radiale  pour  l’angioplastie  coronaire  percutanée  est  associé  à
un meilleur  pronostic  dans  le  contexte  de  l’infarctus  du  myocarde  mais  les  patients  en  choc
cardiogénique  ont  été  exclus  de  la  plupart  des  études.
But. —  Il  s’agit  d’évaluer  le  pronostic  des  patients  en  choc  cardiogénique  en  post-infarctus  du
myocarde  traités  par  angioplastie  par  voie  radiale  en  comparaison  à  la  voie  fémorale.
Méthodes.  — Une  cohorte  prospective  de  101  patients  consécutifs  admis  pour  angioplastie  pour
un choc  cardiogénique  lié  à  un  infarctus  du  myocarde  ont  été  traités  par  voie  radiale  (n  =  74)
ou fémorale  (n  =  27).  Un  modèle  de  Cox  ajusté  sur  des  variables  pré-spéciﬁées  et  un  score  de
propension pour  la  voie  d’abord  ont  été  utilisés  pour  évaluer  la  mortalité,  le  critère  combiné
décès/infarctus/accident  vasculaire  cérébral  et  les  saignements  entre  les  2  groupes.  Une  méta-
analyse complémentaire  incluant  6  études  a  également  été  réalisée.
Résultats.  — Dans  le  groupe  radial,  les  patients  étaient  plus  jeunes  (p  =  0,03),  plus  souvent
masculin  (p  =  0,002),  avaient  un  score  de  GRACE  et  de  CRUSADE  (p  =  0,002  et  0,001),  un  taux
d’arrêt cardiaque  avant  angioplastie  (p  =  0,009)  et  de  ventilation  mécanique  (p  =  0,006)  plus
faible. Le  succès  des  angioplasties  était  comparable  entre  les  2  groupes.  Sur  un  suivi  moyen
de 756  jours,  un  décès  est  survenu  chez  40  patients  (54,1  %)  dans  le  groupe  radial  contre  22
(81,5 %)  dans  le  groupe  fémoral  (HR  :  0,49  ;  IC  95  %  :  0,28—0,84  ;  p  =  0,01).  La  voie  radiale
était associée  à  une  réduction  du  critère  combiné  décès/infarctus/accident  vasculaire  cérébral
(HR :  0,53  ;  IC  95  %  :  0,31—0,91  ;  p  =  0,02)  et  des  saignements  majeurs  (HR  :  0,34  ;  IC  95  %  :
0,13—0,87 ;  p  =  0,02).  La  méta-analyse  a  conﬁrmé  le  bénéﬁce  de  la  voie  radiale  sur  la  mortalité
(RR :  0,63  ;  IC  95  %  :  0,58—0,68)  et  les  saignements  majeurs  (RR  :  0,43  ;  IC  95  %  :  0,32—0,59).
Conclusion.  —  La  voie  radiale  pour  l’angioplastie  coronaire  dans  le  cadre  du  choc  cardiogénique
d’origine ischémique  est  associée  à  une  réduction  majeure  de  la  mortalité,  des  événements
ischémiques  et  hémorragiques  et  doit  être  préférée  à  l’approche  fémorale  dans  les  centres
radialistes experts.
©  2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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mackgroundardiogenic  shock  (CS),  with  a  reported  incidence  of  4—7%,
s  the  leading  cause  of  death  in  patients  with  acute
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ayocardial  infarction  (MI)  [1,2]. The  randomized  SHOCK
rial  showed  that  a  strategy  of  early  revascularization,  with
urgery  or  percutaneous  coronary  intervention  (PCI),  was
ssociated  with  higher  survival  rates  [3]  than  a  strategy  of
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mTransradial  approach  for  PCI  in  cardiogenic  shock  
initial  medical  stabilization.  The  rate  of  PCI  in  CS  patients
has  increased  markedly  since  the  publication  of  these  results
[1].
The  advantage  of  the  transradial  approach  for  PCI  over
transfemoral  access  in  the  setting  of  ST-segment  elevation
myocardial  infarction  has  been  reported  by  different  trials
[4—6].  In  a  recent  meta-analysis  [7],  transradial  PCI  was
associated  with  a  decreased  risk  of  mortality  and  major
bleeding  compared  with  transfemoral  PCI.  Recent  European
Society  of  Cardiology  guidelines  for  the  management  of
patients  with  ST-elevation  MI  state  that  radial  access  for  PCI
should  be  preferred  if  performed  by  an  experienced  radial
operator  [8],  and  a  recent  expert  consensus  paper  suggested
the  use  of  transradial  procedures  if  the  radial  artery  is  palpa-
ble  in  patients  with  CS  [9].  However,  most  studies  excluded
patients  with  CS,  and  the  use  of  transradial  PCI  in  CS  has
been  scarcely  assessed.
The  aim  of  our  study  was  to  compare  outcomes  —  major
adverse  cardiac  events  and  bleeding  complications  —  in  a
cohort  of  consecutive  patients  with  ischaemic  CS  treated
with  transradial  versus  transfemoral  PCI  in  a  radial-ﬁrst  cen-
tre.  We  also  performed  a  meta-analysis  of  the  current  and
similar  published  studies  evaluating  the  outcome  of  PCI  in
CS  based  on  vascular  access  site.
Methods
Patient selection
Between  April  2004  and  December  2011,  6245  patients  were
referred  to  our  hospital  for  PCI  for  MI.  Radial  access  was  the
default  approach  for  performing  PCI  in  our  centre  during  the
whole  period  in  all  settings.  PCI  was  performed  by  experi-
enced  interventional  cardiologists  for  both  transradial  (>200
radial  PCIs/year/operator)  and  transfemoral  access.  Among
all  the  patients,  408  (6.5%)  were  diagnosed  with  CS  before
angiography.  The  criteria  for  CS  were  systolic  blood  pressure
<90  mmHg  for  at  least  30  minutes  or  the  need  for  supportive
measures  to  maintain  a  systolic  blood  pressure  >90  mmHg
and  end-organ  hypoperfusion  (cool  extremities  or  urine  out-
put  <30  mL/hour  with  a  heart  rate  >60  beats  per  minute)  [3].
Only  patients  with  CS  of  ischaemic  origin  occurring  before
angiography  with  an  indication  for  PCI  were  included.  We
excluded  patients  with  CS  of  other  aetiologies  and  those
who  could  have  undergone  angiography  through  one  of
the  approaches  only  (extracorporeal  membrane  oxygenation
before  PCI,  patients  with  bilateral  mammary  artery  or  radial
coronary  bypass  grafts,  severe  peripheral  artery  disease  or
radial  arteriovenous  ﬁstula).  Both  vascular  access  and  intra-
aortic  balloon  pump  (IABP)  use  were  at  the  discretion  of  the
operators.  Patients’  initial  clinical  characteristics,  including
GRACE  and  CRUSADE  scores  [10,11],  pharmacological  treat-
ment,  IABP  status,  details  of  the  procedure,  and  clinical
evolution  during  the  course  of  the  patients’  hospital  stay
and  after  discharge,  were  collected.
ProcedureThe  use  of  antiplatelet  agents,  anticoagulants  and  glyco-
protein  IIb/IIIa  inhibitors  was  at  the  treating  physician’s
discretion,  consistent  with  current  guidelines.  All  PCI
S
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rocedures  were  retrospectively  reviewed  by  two  indepen-
ent  interventional  cardiologists,  to  collect  supplementary
rocedural  characteristics.  Successful  PCI  was  deﬁned  as  a
esidual  diameter  stenosis  of  <30%  and  a  thrombolysis  in
yocardial  infarction  (TIMI)  3  ﬂow  in  the  culprit  vessel  after
he  procedure.  After  the  procedure,  femoral  access  closure
as  managed  by  manual  compression  (n  =  9;  33.3%),  vas-
ular  closure  device  (n  =  6;  22.2%)  or  replacement  by  IABP
n  =  12;  44.4%).  In  the  case  of  a  radial  approach,  haemostasis
as  achieved  with  a  compressive  device  (TR  Band;  Terumo,
okyo,  Japan).
utcomes
he  primary  endpoint  of  the  study  was  the  occurrence  of
eath.  Secondary  major  endpoints  were  the  occurrence  of
he  composite  of  death,  stroke  or  new  MI,  major  bleeding
nd  net  clinical  beneﬁt.  Cardiac  death  was  deﬁned  as  any
eath  due  to  a  cardiac  cause.  Deaths  from  unknown  cause
ere  considered  as  cardiac.  New  MI  was  deﬁned  as  new
schaemic  symptoms  lasting  >20  minutes  and  new  or  recur-
ent  ST-segment  elevation  or  depression  >1  mV  in  at  least
wo  contiguous  leads,  associated  with  a new  >20%  increase  in
ardiac  biomarkers  levels,  not  attributable  to  the  evolution
f  the  index  MI.
Minor  and  major  bleedings  were  deﬁned  according  to
he  TIMI  deﬁnition  [12].  Bleeding  was  further  categorized
s  access  site  related  or  non-access  site  related.  Follow-up
ata  (rehospitalization  for  heart  failure,  blood  transfusions
nd  new  revascularization)  were  collected.  New  revascu-
arization  was  deﬁned  as  any  revascularization  procedure
erformed  because  of  angiographic  stenosis  or  thrombo-
is  associated  with  clinical  and/or  objective  evidence  of
yocardial  ischaemia.  Net  clinical  beneﬁt  was  deﬁned  by
he  composite  of  death,  stroke,  MI  or  major  bleeding.
The  patients,  their  families  or  their  general  practitioner
nd/or  cardiologist  were  contacted  in  December  2012  to
ssess  clinical  follow-up  after  discharge  in-hospital  sur-
ivors.
eta-analysis
e  conducted  a  systematic  literature  review  by  formal
earches  of  the  MEDLINE  electronic  database  covering
he  period  from  January  2000  to  June  2014.  Relevant
tudies  were  identiﬁed  using  a  combination  of  medical
ubject  headings,  including  the  following  terms:  ‘car-
iogenic  shock’,  ‘myocardial  infarction’,  ‘PCI’,  ‘vascular
ccess’,  ‘transradial  access’  and  ‘radial  approach’.  Refer-
nces  from  reviews  and  selected  articles  were  also  reviewed
or  potential  relevant  citations.  Studies  were  selected  by
wo  independent  reviewers  (V.R.  and  A.L.).  We  restricted
ur  analysis  to  studies  that  met  all  of  the  following  inclusion
riteria:  outcome  comparison  of  transradial  and  trans-
emoral  access  for  PCI  in  CS  patients;  and  available  data
n  mortality.  Exclusion  criteria  were  ongoing  studies  and
rretrievable  data.  The  endpoints  were  all-cause  death,
ajor  bleeding  and  transfusion.tatistical analysis
roups  were  deﬁned  by  transradial  or  transfemoral
pproach.  Continuous  variables  are  expressed  as  mean
5 V.  Roule  et  al.
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Figure 1. Kaplan-Meier survival curves for radial versus femoral
groups (P < 0.01), with adjustment for age, sex, previous peripheral
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alues  ±  standard  deviations  and  were  compared  using  Stu-
ent’s  test.  Categorical  variables  are  expressed  as  numbers
f  patients  and  percentages  and  were  compared  using  the
2 test.  The  Kaplan-Meier  estimator  and  log-rank  test  were
sed  to  compare  survival  between  the  two  groups.  A  Cox
roportional  hazards  model  adjusted  for  prespeciﬁed  varia-
les  (age,  sex,  previous  peripheral  vascular  disease,  GRACE
core,  CRUSADE  score  [for  bleeding  only]  and  need  for
ABP)  was  used  for  the  primary  analysis  to  assess  mor-
ality,  combined  endpoints  of  death/stroke/recurrent  MI,
leeding  and  net  clinical  beneﬁt,  in  the  two  groups.  A  com-
lementary  analysis  was  performed  using  a  Cox  proportional
azards  model  adjusted  for  the  prespeciﬁed  variables  as
ell  as  deciles  of  the  propensity  score  for  choosing  radial
ccess.  The  propensity  score  was  calculated  using  a logistic
egression  model  that  included  the  following  prespeciﬁed
ariables:  age,  sex,  diabetes  mellitus,  cigarette  smoker,
eight,  history  of  peripheral  vascular  disease,  vitamin  K
ntagonist  treatment  and  systolic  blood  pressure.
The  results  of  the  meta-analysis  are  presented  as  rela-
ive  risks  with  95%  conﬁdence  intervals  (CIs).  Outcomes  from
ndividual  studies  were  combined  using  the  Mantel-Haenszel
xed-effect  (primary  analysis)  and  random-effect  (sensitiv-
ty  analysis)  models.  The  ﬁxed-effect  model’s  relative  risks
re  reported  in  the  text.  All  tests  were  two-tailed  and  a
-value  of  <0.05  was  considered  statistically  signiﬁcant.
R  software,  version  3.0.0  (2013-04-03)  for  MacOS  (R  Foun-
ation  for  Statistical  Computing,  Vienna,  Austria)  was  used
or  statistical  analysis  and  meta-analysis.
esults
 total  of  101  consecutive  patients  were  included,  of  whom
4  (73.3%)  were  treated  by  the  transradial  approach  and
7  (26.7%)  by  the  transfemoral  approach.  Patients’  clini-
al  characteristics  and  treatments  are  detailed  in  Table  1.
atients  aged  >75  years  accounted  for  41.6%  (n  =  42)  of  the
ohort,  with  a  similar  distribution  between  groups.
rocedure
ngiographic  ﬁndings  and  PCI  procedures  are  summarized  in
able  2,  showing  similar  rates  of  procedural  success  (overall
CI  success  rate  of  70.3%).  Final  TIMI  3  ﬂow  was  observed
n  81  patients  (80.2%)  and  did  not  differ  between  groups
62  patients  in  the  transradial  group  versus  19  patients  in
he  transfemoral  group;  P  =  0.13).  There  were  no  crossovers
etween  the  groups.
utcomes
uring  the  2.1  ±  2.6  years  of  follow-up,  62  patients  (61.4%)
ied  (Fig.  1).  Outcomes  are  detailed  in  Table  3.
In  the  transradial  group,  IABP-related  complications
ere  one  femoral  artery  dissection,  one  acute  lower  limb
schaemia  and  two  local  venous  thromboses.  In  the  trans-
emoral  group,  IABP-related  complications  were  one  artery
issection,  one  intestinal  ischaemia,  one  minor  bleeding,
ne  local  venous  thrombosis  and  one  documented  device
nfection.
O
p
cascular disease, need for IABP, GRACE score (and CRUSADE score
or bleeding).
All  unadjusted  and  adjusted  Cox  proportional  hazards
odels  demonstrated  that  the  transradial  approach  com-
ared  with  the  transfemoral  approach  was  associated  with
n  improved  outcome  for  all  endpoints,  independent  of  co-
ariables.  All  results  are  detailed  in  Table  4.
eta-analysis
ix  studies,  including  ours,  were  included  in  the  meta-
nalysis  (Fig.  2)  [13—17]. Mortality  data  were  collected  at  30
ays  for  all  studies  except  one  [17],  where  only  in-hospital
ortality  was  reported.  Major  bleeding  and  transfusion  data
ere  collected  during  hospital  stay,  except  in  one  study  [15]
here  major  bleeding  (but  not  transfusion)  was  reported
t  30  days.  Major  bleeding  complications  were  deﬁned
ccording  to  the  TIMI  haemorrhage  classiﬁcation  [13]  or
tudy-speciﬁc  criteria  [14—17].  Patients’  major  character-
stics  and  endpoint  results  are  detailed  for  each  study  in
able  5.
The  meta-analysis  conﬁrmed  that  transradial  access  was
ssociated  with  lower  rates  of  mortality  (relative  risk  [RR]:
.63,  95%CI:  0.58—0.68;  Fig.  3A),  major  bleeding  (RR:  0.43,
5%CI:  0.32—0.59;  Fig.  3B)  and  transfusion  (RR:  0.49,  95%CI:
.35—0.67;  Fig.  3C),  without  heterogeneity  among  studies
xcept  for  transfusion  rates.
iscussionur  study  showed  that  the  transradial  approach  for  PCI  in
atients  with  acute  MI  complicated  by  CS  could  be  used  suc-
essfully  in  >70%  of  the  cases  in  a  ‘radial-ﬁrst  approach’
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Table  1  Patients’  characteristics  at  admission.
All  (n  = 101)  Radial  (n  =  74)  Femoral  (n  =  27)  P
Baseline  patient  characteristics
Age  (years)  68.0  ±  13.0  67.0  ±  13.6  73.0  ±  10.3  0.039
Men  69  (68.3)  57  (77.0)  12  (44.4)  0.002
Risk  factors
Systemic  hypertension  55  (54.5)  39  (52.7)  16  (59.3)  0.56
Diabetes  mellitus  29  (28.7)  18  (24.3)  11  (40.7)  0.11
Hyperlipidaemia  42  (41.6)  31  (41.9)  11  (40.7)  0.92
Current  cigarette  smoker 28  (27.7) 23  (31.1) 5  (18.5) 0.21
Family  history  of  premature  coronary  disease 12  (11.9) 10  (13.5) 2  (7.4) 0.40
Body  mass  index  (kg/m2) 26.9 ±  4.9 27.3  ±  5.1 25.9  ±  4.1 0.21
History
Myocardial  infarction  14  (13.9)  9  (12.2)  5  (18.5)  0.41
Coronary  artery  bypass  2  (2.0)  2  (2.7)  0  (0)  0.39
PCI  10  (9.9) 7  (9.5) 3  (11.1)  0.81
Peripheral  vascular  disease 9  (8.9) 6  (8.1) 3  (11.1)  0.64
Vitamin  K  antagonist  treatment 7  (6.9) 5  (6.8) 2  (7.4)  0.91
Presenting  characteristics
Creatinine  clearance  rate  (mL/min) 55.8  ±  27.0 58.4  ±  25.5 48.6  ±  29.9 0.11
Clearance  <30  mL/min 14  (13.9) 5  (6.8) 9  (33.3) 0.001
Systolic  blood  pressure  (mmHg) 77.4  ±  14.2 78.6  ±  13.0 73.9  ±  16.7 0.14
Diastolic  blood  pressure  (mmHg)  49.3  ±  12.6  50.6  ±  12.2  45.5  ±  13.1  0.07
Heart  rate  (beats  per  minute)  80.6  ±  31.8  77.5  ±  31.6  89  ±  31.2  0.11
Cardiac  arrest  before  PCI  26  (25.7)  14  (18.9)  12  (44.4)  0.009
Shock  at  admission  55  (54.5)  40  (54.1)  15  (55.6)  0.89
Time  between  shock  and  PCI  (hours)  3.8  ±  10.6  4.1  ±  11.9  3.1  ±  5.5  0.67
Mechanical  ventilation  56  (55.4)  35  (47.3)  21  (77.8)  0.006
LVEF  at  presentation  (%)  36.9  ±  13.3  37.3  ±  14.3  35.9  ±  10.3  0.64
GRACE  score  250.8  ±  34.1  244.7  ±  31.3  267.4  ±  36.5  0.003
CRUSADE  score  5.1  ±  12.2  48.7  ±  11.3  57.4  ±  12.5  0.001
ST-segment  elevation  91  (90.1)  67  (90.5)  24  (88.9)  0.81
Treatment
Aspirin  101  (100)  74  (100)  27  (100)  —
Clopidogrel  99  (98.0)  72  (97.3)  27  (100)  0.39
Prasugrel  2  (2.0)  2  (2.7)  0  (0)  0.39
Unfractionated  heparin  87  (86.1)  63  (85.1)  24  (88.9)  0.63
Enoxaparin  4  (4.0)  4  (5.4)  0  (0)  0.22
Fondaparinux  7  (6.9)  5  (6.8)  2  (7.4)  0.91
Bivalirudin  1  (1.0)  1  (1.4)  0  (0)  0.54
Glycoprotein  IIb/IIIa  inhibitor  35  (34.7)  28  (37.8)  7  (25.9)  0.27
Prehospital  ﬁbrinolysisa 39  (42.9)  31  (46.3)  8  (33.3)  0.26
IABP  71  (70.3)  51  (68.9)  20  (74.1)  0.62
Before  PCI  30  (29.7)  25  (33.8)  5  (18.6)  0.07
Duration  (days)  3.5  ±  1.9  3.44  ±  1.9  3.8  ±  2.1  0.82
Inotropic  drugs  94  (93.1)  68  (91.9)  26  (96.3)  0.44
Data are expressed as mean ± standard deviation or number (%). IABP: intra-aortic balloon pump; LVEF: left ventricular ejection fraction;
PCI: percutaneous coronary intervention.
a In patients with ST-segment elevation.
r
wcentre  with  no  crossover  to  femoral  access.  This  approach
appeared  to  be  safer,  with  a  three-fold  lower  incidence
of  bleeding  complications  compared  with  the  transfemoral
approach,  and  was  associated  with  a  higher  survival  rate
and  a  reduction  in  major  adverse  cardiac  events.  The
meta-analysis  (including  our  data)  conﬁrmed  the  dramatic
t
m
reduction  in  mortality  and  major  bleeding  rates  associated
ith  the  transradial  approach.
The  SHOCK  trial  demonstrated  that  early  revasculariza-ion  in  patients  with  acute  MI  complicated  by  CS  reduced
ortality  in  patients  aged  <75  years  [3].  As  a  consequence,
ates  of  PCI  in  CS  patients  have  dramatically  increased  in
568  V.  Roule  et  al.
Table  2  Angiographic  data.
All  (n  =  101)  Radial  (n  =  74)  Femoral  (n  =  27)  P
Angiography
Right  radial  approach  98  (97)  72  (97.3)  26  (96.3)  0.79
MVD  78  (77.2)  58  (78.4)  20  (74.1)  0.41
LM  stenosis  >50%  21  (20.8)  16  (21.6)  5  (18.5)  0.73
Culprit  coronary  artery
LAD  48  (47.5) 33  (44.6) 15  (55.6) 0.33
LCx  8  (7.9) 6 (8.1) 2  (7.4) 0.91
RCA  31  (30.7)  24  (32.4)  7  (25.9)  0.53
LM  13  (12.9)  10  (13.5)  3  (11.1)  0.75
Saphenous  graft  1  (1.0)  1  (1.4)  0  (0)  0.54
Approach
≤6  French  98  (97.0)  74  (100)  24  (88.9)  0.004
Number  of  diagnostic  catheters  1.0  ±  0.8  1.1  ±  0.9  0.7  ±  0.7  0.38
PCI
Number  of  PCI  catheters  1.6  ±  0.8  1.5  ±  0.7  1.7  ±  0.8  0.16
Thrombectomy  12  (11.9)  11  (14.9)  1  (3.7)  0.13
Bare-metal  stent  79  (78.2)  54  (73.0)  25  (92.6)  0.034
Number  of  stents  1.7  ±  0.8  1.6  ±  0.8  2.0  ±  0.9  0.21
Number  of  revascularized  vessels  1.2  ±  0.4  1.2  ±  0.4  1.2  ±  0.4  0.79
Complete  revascularization  67  (66.3)  51  (68.9)  16  (59.3)  0.36
Procedure  success  71  (70.3)  54  (73.0)  17  (63.0)  0.33
Procedure  time  (minutes)a 72.2  ±  40.3  72.6  ±  38.8  71.0  ±  45.8  0.87
Fluoroscopy  time  (minutes)b 14.9  ±  9.8  15.6  ±  9.8  12.7  ±  9.8  0.24
Contrast  media  volume  (mL)c 221.6  ±  102.8  231.4  ±  108.8  192.9  ±  78.0  0.15
Complications
No-reﬂow  13  (12.9)  11  (14.9)  2  (7.4)  0.32
Coronary  dissection  2  (2.0)  2  (2.7)  0  (0)  0.39
Side-branch  occlusion  3  (3.0)  1  (1.4)  2  (7.4)  0.11
Distal  embolization  6  (5.9)  4  (5.4)  2  (7.4)  0.71
Data are expressed as number (%) or mean ± standard deviation. ACE: angiotensin-converting enzyme; LAD: left anterior descending
coronary artery; LCx: left circumﬂex coronary artery; LM: left main; MVD: multivessel disease; PCI: percutaneous coronary intervention;
RCA: right coronary artery.
a Data available for 90 patients.
b Data available for 85 patients.
c Data available for 79 patients.
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bhe  last  20  years  [1].  In  parallel,  the  radial  approach  has
een  used  increasingly  for  PCI.  The  beneﬁts  of  transradial
ccess  for  PCI  compared  with  transfemoral  access  in  the
etting  of  ST-elevation  MI  have  been  reported  in  different
rials  [4—6].  However,  most  of  these  trials  excluded  patients
ith  CS.  So  far,  studies  focusing  on  transradial  access  for  PCI
n  CS  patients  are  scarce  [13—17].  Reported  rates  of  radial
pproach  in  such  studies  range  from  26—70%  of  all  proce-
ures.  In  our  study,  the  rate  of  PCI  via  radial  access  was
igher  (73.3%)  than  most  studies;  this  ﬁnding  may  reﬂect  the
igh  expertise  in  radial  use  in  our  centre,  where  the  radial
pproach  started  more  than  5  years  before  the  current  data
ollection  period.  Mamas  et  al.  [16]  recently  reported  data
n  the  nationwide  practice  of  PCI  in  the  UK,  showing  highly
ariable  rates  of  radial  approach  use  between  centres,  with
n  overall  rate  of  use  of  only  26%.  The  feasibility  of  PCI  by
adial  access  is  clearly  lower  than  the  90%  recently  described
n  a  ‘real-life’  population  of  uncomplicated  ST-elevation
I  [18].  Indeed,  CS  is  a  strong  independent  predictor  of
r
r
transradial  approach  PCI  failure  [19].  Nevertheless,  the  rate
f  radial  access  in  our  study  remained  high,  considering  the
ritical  basal  status  of  our  population,  underlined  by  the  high
roportion  of  patients  requiring  inotropic  drugs  —  nearly  six-
old  higher  than  the  rate  reported  by  Mamas  et  al.  [16].
his  is  probably  a  consequence  of  their  deﬁnition  of  CS,
ith  a  blood  pressure  threshold  <100  mmHg  rather  than  the
90  mmHg  usually  used  in  other  studies.  Our  procedural  suc-
ess  rate  of  70.3%  is  broadly  similar  to  previous  series  in  CS
13,14,16], with  the  exception  of  one  study  that  reported
n  impressive  success  rate  of  95.3%  [15].
The  clinical  beneﬁt  of  transradial  access  in  terms  of
leeding  and  mortality  is  the  most  important  ﬁnding  of
ur  study.  The  beneﬁts  of  transradial  compared  with  trans-
emoral  access  for  PCI  in  the  setting  of  ST-elevation  MI  have
een  reported  by  different  trials  [4—6]. A  meta-analysis  of
ecent  trials  showed  that,  compared  with  femoral  access,
adial  access  was  associated  with  a  nearly  two-fold  reduc-
ion  in  the  odds  of  death  and  a  1.5-fold  reduction  in  the  odds
Transradial  approach  for  PCI  in  cardiogenic  shock  569
Table  3  Clinical  outcomes.
All  (n  =  101)  Radial  (n  =  74)  Femoral  (n  =  27)  P
In-hospital  outcome
Death  47  (46.5)  28  (37.8)  19  (70.4)  0.0037
PCI  vascular  site  complication  4  (4.0)  0  (0)  4  (14.8)  0.0007
IABP  vascular  site  complication 9  (8.9) 4  (5.4)  5  (18.5)  0.041
Transfusion 30  (29.7) 20  (27.0) 10  (37.0)  0.33
Bleeding
Any  18  (17.8)  10  (13.5)  8  (29.6)  0.06
Major  5  (5.0)  1  (1.4)  4  (14.8)  0.006
Maximum  Hb  loss  (g/dL)  0.73  ±  1.8  0.5  ±  1.6  1.4  ±  2.2  0.021
Outcome  at  follow-up
Follow-up  time  (days)  756.9  ±  961.5  864.5  ±  979.0  462.0  ±  860.9  0.06
Death  62  (61.4)  40  (54.1)  22  (81.5)  0.012
Cardiac  death  51  (50.5)  35  (47.3)  16  (59.3)  0.29
Recurrent  myocardial  infarction  4  (4.0)  3  (4.1)  1  (3.7)  0.94
Any  new  revascularization  10  (9.9)  9  (12.2)  1  (3.7)  0.21
Stroke  1  (1.0)  0  (0)  1  (3.7)  0.10
Rehospitalization  for  HF  8  (7.9)  7  (9.5)  1  (3.7)  0.34
Composite  endpoints
Death  and  new  MI  64  (63.4)  42  (56.8)  22  (81.5)  0.022
Death,  stroke  or  new  MI 64  (63.4)  42  (56.8)  22  (81.5)  0.022
Bleeding
Any  21  (20.8)  12  (16.2)  9  (33.3)  0.06
Major  5  (5.0) 1  (1.4)  4  (14.8)  0.006
Data are expressed as number (%) or mean ± standard deviation. Hb: haemoglobin; HF: heart failure; IABP: intra-aortic balloon pump;
MI: myocardial infarction; PCI: percutaneous coronary intervention.
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iof  major  adverse  cardiac  events  in  ST-elevation  MI  patients
undergoing  primary  PCI  [7].  However,  patients  with  CS  were
excluded  from  most  of  these  trials,  except  RIFLE-STEACS,
where  an  IABP  was  used  in  8%  of  the  patients  [6].  Never-
theless,  the  details  of  such  a  subgroup  are  not  reported.
Herein  we  reported  our  radial  experience  in  CS,  showing
a  substantial  reduction  in  mortality,  major  adverse  cardiac
events  and  bleeding  associated  with  radial  access.  The  mor-
tality  reduction  in  similar  studies  was  variable  but  consistent
between  the  three  largest  studies  [13,16,17].  Nevertheless,
the  results  of  these  studies  may  be  tempered,  as  patients
with  transfemoral  access  were  more  critically  ill,  as  outlined
by  higher  rates  of  mechanical  ventilation  before  PCI  and
p
m
p
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Table  4  Cox  proportional  hazard  models.
Unadjusted  
HR  (95%CI)  P  
All-cause  death  0.46  (0.27—0.77)  <0.01  
Death,  stroke  or  new  infarction  0.49  (0.29—0.83)  <0.01  
Bleeding  0.30  (0.12—0.71)  <0.01  
Net  clinical  beneﬁt  0.43  (0.26—0.70)  <0.001  
CI: conﬁdence interval; HR: hazard ratio.
a Adjusted for age, sex, previous peripheral vascular disease, need for
for bleeding).
b Further adjusted for propensity score.iabetes  [13,16,17],  more  frequent  use  of  inotrope  or  IABP
upport  and  renal  insufﬁciency  [16,17]  and  lower  systolic
nd  diastolic  pressures  [17]  compared  with  the  transradial
roup.  Concordantly  in  our  study,  the  transradial  approach
as  associated  with  lower  predictors  of  poor  outcome,  as
ttested  by  lower  GRACE  and  CRUSADE  scores  [10,11,20].
evertheless,  the  persistence  of  a  similar  superiority  of
he  transradial  approach  after  adjustment  for  co-variables,
ncluding  risk  scores  and  the  propensity  score,  highlights  the
robable  independence  of  such  a  relationship.  The  similar
agnitude  of  mortality  reduction  in  the  current  study  and
rior  studies  also  tends  to  underscore  the  robustness  of  the
ndings.
Adjusteda PS-adjustedb
HR  (95%CI)  P  HR  (95%CI)  P
0.49  (0.28—0.84)  0.01  0.37  (0.18—0.75)  <0.01
0.53  (0.31—0.91)  0.02  0.37  (0.18—0.75)  <0.01
0.34  (0.13—0.87)  0.02  0.33  (0.12—0.94)  0.04
0.52  (0.30—0.89)  0.02  0.39  (0.20—0.78)  <0.01
 intra-aortic balloon pump and GRACE score (and CRUSADE score
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Table  5  Patients’  characteristics  and  endpoints  from  studies  included  in  the  meta-analysis.
Rodriguez  (n  =  122)  Bernat  (n  =  197)  Fujii  (n  =  81)  Mamas  (n  =  7231)  Iga  (n  =  85)  Roule  (n  =  101)
Radial  approach  80  (65.6)  108  (55.0)  38  (46.9)  1877  (26.0)  60  (70.6)  74  (73.3)
Age  (years)  66.0  ±  12.0  66.0  ±  12.0  71.9  ±  11.0  67.2  ±  0.3  68.8  ±  11.4  68.0  ±  13.0
Men  102  (83.6)  140  (77.0)  61  (75.3)  5055  (70.1)  68  (80.0)  69  (68.3)
Risk  factors
Systemic  hypertension  70  (57.4)  99  (50.3)  71  (87.6)  3149  (43.5)  48  (56.5)  55  (54.5)
Diabetes  mellitus  53  (43.4)  37  (18.8)  45  (55.6)  1338  (18.5)  30  (35.3)  29  (28.7)
Hyperlipidaemia  67  (55.0)  82  (42.0)  44  (54.3)  3060  (42.3)  39  (45.9)  42  (41.6)
Active  cigarette  smoker  40  (32.8)  80  (41.0)  47  (58.0)  1754  (24.3)  45  (52.9)  28  (27.7)
Family  history  of  coronary  disease  —  —  9  (11.1)  —  16  (18.8)  12  (11.9)
Body  mass  index  (kg/m2)  27.4  ±  5.0  26.0  ±  4.0  23.4  ±  3.8  —  23.6  ±  3.8  26.9  ±  4.9
History
Myocardial  infarction  41  (33.6)  31  (16.0)  11  (13.6)  1506  (20.8)  8  (9.4)  14  (13.9)
Coronary  bypass  5  (4.1)  2  (1.0)  1  (1.2)  331  (4.6)  1  (1.2)  2  (2.0)
PCI  10  (8.2)  19  (9.8)  7  (8.6)  865  (12.0)  8  (9.4)  10  (9.9)
Peripheral  vascular  disease  41  (33.6)  —  —  —  0  (0)  9  (8.9)
ST-segment  elevation  89  (72.9)  197  (100)  81  (100)  5493  (76.0)  78  (91.8)  91  (90.1)
Time  between  shock  and  PCI  (minutes)  227  (106—435)  231  (151—389)  115.2  ±  45.1  —  102.9  ±  38.7  228.0  ±  636.0
Biology  at  presentation
Creatinine  clearance  rate  (mL/min)  61  ±  32.0  72  ±  35.0  51.2  ±  17.8  —  —  55.8  ±  27.0
Hb  (g/dL)  —  13.8  ±  2.0  13.0  ±  3.4  —  —  12.8  ±  2.2
Systolic  blood  pressure  (mmHg)  76.0  ±  17.0  —  77.6  ±  39.6  —  46.8  ±  44.3  77.4  ±  14.2
Diastolic  blood  pressure  (mmHg)  46.0  ±  14.0  —  31.9  ±  32.1  —  —  49.3  ±  12.6
Heart  rate  (beats  per  minute)  87.0  ±  30.0  —  75.9  ±  29.8  —  54.5  ±  41.4  80.6  ±  31.8
Cardiac  arrest  before  PCI  —  —  38  (46.9)  —  26  (30.6)  26  (25.7)
Mechanical  ventilation  61  (50.0)  131  (66.5)  —  1954  (27.0)  —  56  (55.4)
LVEF  at  presentation  (%)  33.0  ±  15.0  —  —  —  42.8  ±  15.5  36.9  ±  13.3
Transradial
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Table  5 (Continued)
Rodriguez  (n  =  122) Bernat  (n  =  197) Fujii  (n  =  81) Mamas  (n  =  7231) Iga  (n  =  85) Roule  (n  =  101)
Aspirin  109  (89.3) —  —  —  —  101  (100)
Clopidogrel  84  (68.8) —  —  —  —  99  (98.0)
Heparin  46  (37.7) —  —  —  —  97  (90.1)
Glycoprotein  IIb/IIIa  inhibitors 60  (49.2) 80  (41.0) —  3954  (54.7) —  35  (34.7)
IABP  52  (42.6) 88  (45.0) 54  (66.7) 2446  (33.8) 76  (89.4) 71  (70.3)
Inotropic  drugs 88 (72.1) —  —  1153  (15.9) —  94  (93.1)
Procedure  success 92  (75.4) —  78  (96.3)  —  81  (95.3)  71  (70.3)
Final  TIMI  3  grade  —  134  (68.0)  66  (81.5)  —  —  81  (80.2)
Procedure  time  (minutes) — 47  (35—66) 125.1  ±  46.4 —  —  72.2  ±  40.3
Fluoroscopy  time  (minutes) 15.8  ±  11.6 10  (6—17)  —  —  30.8  ±  18.3  14.9  ±  9.8
Dose  surface  product  (cGy.cm2)  2842.5  ±  5101.5  —  —  —  1225.0  ±  886.0  4723.2  ±  3303.6
Contrast  media  volume  (mL)  244.0  ±  129.0  170  (130—200)  237.1  ±  102.1  —  184.1  ±  66.5  221.6  ±  102.8
Endpoints
Death  53  (43.4) 91  (46.2) 22  (27.2) 2296  (31.8) 26  (30.6) 47  (46.5)
Major  bleeding 15  (12.3) 36  (18.3) 1  (1.2) 192  (3.0) 11  (12.9) 5  (5.0)
Transfusion 24  (19.7) 41  (20.8) 4  (4.9) 127  (1.8) —  30  (29.7)
Data are expressed as number (%), mean ± standard deviation or median (interquartile range). Hb: haemoglobin; LEVF: left ventricular ejection fraction; PCI: percutaneous coronary
intervention; TIMI: thrombolysis in myocardial infarction.
572  V.  Roule  et  al.
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tigure 2. Flow diagram of the study selection.
The  proportion  of  patients  with  ST-elevation  MI  and  non-
T-elevation  MI  differed  between  studies  and  may  explain
ome  differences.  Indeed,  the  beneﬁt  of  radial  access  on
ortality  was  not  observed  in  patients  with  non-ST-segment
levation  acute  coronary  syndrome  in  the  RIVAL  trial  [5].
owever,  our  meta-analysis  conﬁrmed  the  overall  reduction
f  mortality  in  CS  with  radial  access.  Moreover,  the  ben-
ﬁts  of  transradial  access  in  our  cohort  persisted  despite
igh  rates  of  IABP  use  (70.3%),  as  previously  described  in
he  RADIAL  PUMP  UP  registry  [21].  In  the  setting  of  CS
f  ischaemic  origin,  the  prognosis  is  not  related  to  the
resence  of  ST-segment  elevation,  but  to  revascularization
uccess,  the  extent  of  haemodynamic  compromise  and  pos-
ibly  periprocedural  complications,  such  as  bleeding.
Extensive  data  have  shown  that  bleeding  and  transfu-
ion  in  ACS  are  associated  with  a  high  risk  of  mortality
22,23].  Patients  with  an  acute  coronary  syndrome  compli-
ated  by  CS  are  at  higher  risk  of  major  bleeding  compared
ith  those  without  CS  [2],  and  CS  itself  is  an  independent
isk  factor  for  bleeding  [22].  ST-elevation  MI  patients  rep-
esent  the  majority  of  patients  with  CS  in  published  studies
1,2],  as  well  as  in  our  study  (90%).  Such  patients  are  treated
ith  potent  combinations  of  antiplatelet  and  antithrom-
otic  regimens,  including  ﬁbrinolytic  therapy.  Hence  the
ssociation  between  bleeding  and  mortality  in  this  popu-
ation  is  a  plausible  explanation  for  the  beneﬁt  of  radial
ccess  in  terms  of  the  primary  endpoint  and  mortality
ates  in  patients  with  ST-elevation  MI,  but  not  in  those
ith  non-ST-elevation  MI,  in  the  RIVAL  trial  [5].  The  rate
f  major  bleeding  in  our  cohort  was  similar  to  those  in
revious  studies  in  general  acute  coronary  syndrome  popu-
ations  [23],  but  lower  than  those  reported  in  patients
ith  CS  [13,15,17],  despite  an  important  use  of  prehospital
brinolysis,  similar  demographic  characteristics  and  over-
ll  mortality  rate.  This  may  be  explained  by  the  70%  radial
ccess  rate  and  the  use  of  smaller  diameter  sheaths  (5F  and
w
g
aF)  in  our  centre.  Two  other  studies  reported  a  lower  rate  of
ajor  bleeding  [14,16]. However,  under-reporting  of  bleed-
ng  complications  is  a  common  bias:  outcome  data  were  not
vailable  for  10%  of  the  cohort  in  one  study  [16],  and  no
recise  deﬁnition  of  bleeding  was  provided  in  another  study
14]. Rates  of  major  bleeding  in  general  and  access  site
leeding  were  both  lower  in  the  transradial  group  in  our
tudy.  Major  bleeding  at  the  vascular  site  represents  nearly
0%  of  the  major  bleeding  in  ACSs  [22,24], but  this  rate
eaches  nearly  50%  in  patients  with  ST-elevation  MI  [25].  By
educing  vascular  access  site  complication,  the  transradial
pproach  has  been  reported  to  reduce  transfusion  rates  by
0%  and  to  be  associated  with  a  signiﬁcant  reduction  in  30-
ay  and  1-year  mortality  [26]. One  major  advantage  of  the
rimary  transradial  approach  in  a  critically  ill  population,
articularly  the  elderly  (>40%  of  our  patients),  is  that  these
atients  are  at  highest  risk  of  complications  related  to  the
ransfemoral  approach  [27];  this  may  also  be  an  explanation
or  our  results.
The  majority  of  bleedings  are,  however,  non-access  site
omplications  [22,24].  As  the  vascular  access  in  our  study
as  not  randomized,  we  could  not  exclude  selection  bias.
uch  a  bias  was  minimized  in  our  study,  as  the  model
djusted  for  the  propensity  score  still  conﬁrmed  the  dra-
atic  reduction  in  bleedings  with  radial  access,  with  a
imilar  HR.  A  recent  meta-analysis  showed  that  in  the  set-
ing  of  primary  PCI  for  ST-elevation  MI,  the  risk  of  major
leeding  was  halved  with  the  radial  approach  [7].  When
onsidering  studies  in  CS  patients,  the  reduction  in  major
leeding  remained  variable,  highlighting  the  issue  of  bleed-
ng  deﬁnitions.  However,  our  meta-analysis  also  showed  a
wo-fold  decrease  in  both  major  bleeding  and  transfusion
ith  the  transradial  approach,  without  signiﬁcant  hetero-
eneity  among  studies.
Despite  overwhelming  results  in  favour  of  the  radial
pproach,  this  access  site  is  considered  challenging  by  some
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iFigure 3. Forest plot of included studies for (A) death, (B) majo
conﬁdence interval; RR: relative risk; W: weight.
operators.  The  transradial  technique  requires  speciﬁc  skill
sets  and  follows  a  signiﬁcant  learning  curve.  The  femoral
artery  seems  to  remain  the  preferred  access  site  in  the
most  serious  cases,  even  in  radial-experienced  centres.  One
explanation  may  be  a  poor  or  absent  radial  pulse  result-
ing  from  profound  haemodynamic  compromise.  Supporting
i
H
a
leding and (C) transfusion with radial versus femoral approach. CI:
he  latter  explanation,  Bernat  et  al.  [13]  found  that  an
ntravenous  norepinephrine  bolus,  by  transiently  increas-
ng  blood  pressure,  was  helpful  in  obtaining  radial  access.
aematomas  or  radial  artery  spasm  or  thrombosis,  following
 prior  puncture  of  the  radial  artery  for  arterial  blood  samp-
ing  or  invasive  blood  pressure  monitoring,  may  be  other
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easons  for  the  use  of  femoral  artery  access.  The  demo-
raphic  characteristics  of  patients  with  CS  —  high  rates  of
he  elderly  and  women  —  may  also  explain  the  higher  rates
f  femoral  access,  because  of  the  anticipation  of  poten-
ial  access  difﬁculties  in  such  patients.  The  less  restrictive
hoice  of  sheath  size  (>6F)  with  femoral  access  may  also
xplain  its  preference  in  this  setting.  Finally,  some  opera-
ors  may  prefer  the  femoral  approach  to  have  the  possibility
f  using  IABPs  or  percutaneous  ventricular  assist  devices  dur-
ng  or  following  PCI,  using  the  same  access  site.  However,
he  pertinence  of  such  a  strategy  is  highly  questionable  given
he  high  rate  of  IABP-related  complications  and  the  negative
esults  of  the  IABP-SHOCK  II  trial  [28].
Similar  success  rates  can  be  achieved  with  both
pproaches  with  appropriate  training,  as  outlined  by  the
imilar  rates  of  procedural  success  and  absence  of  site
rossover  in  our  study.  Crossover  to  the  contralateral  artery
s,  in  general,  more  frequent  with  the  radial  than  with  the
emoral  approach  [7],  but  the  rates  of  crossover  decrease
ith  operator  experience.  We  did  not  ﬁnd  differences
etween  the  two  approaches  in  terms  of  contrast  volume
nd  procedural  or  ﬂuoroscopy  times.  This  important  ﬁnding
nderlines  the  fact  that,  when  considered  possible  by  expe-
ienced  operators,  radial  access  does  not  delay  PCI,  even
n  CS  patients.  A  recent  meta-analysis  [7]  in  the  setting  of
rimary  PCI  for  ST-elevation  MI  showed  that,  compared  with
he  femoral  approach,  the  procedure  time  with  the  radial
pproach  was  on  average  only  1.5  minutes  longer,  suggest-
ng  that  procedural  delay  is  not  a  signiﬁcant  concern.  The
eneﬁts  of  radial  access  as  well  as  radiation  doses  again
epend  on  the  experience  of  the  centres.  High-volume  cen-
res  show  better  results  with  the  radial  approach  in  terms  of
ccess  site  crossover,  major  vascular  complications  and  clin-
cal  outcome  [24],  and  differences  in  radiation  dose  between
adial  and  femoral  access  are  present  only  in  lower-volume
entres  and  operators  [29].
Considering  the  results  of  our  study,  we  suggest  that
he  transradial  approach  should  be  the  default  strategy  in
atients  with  CS,  when  considered  feasible  and  performed
y  trained  operators.  In  case  of  radial  puncture  failure,  a
ontralateral  radial  artery  approach  may  be  preferred  to  a
rossover  to  the  femoral  artery  approach,  again,  if  it  is  con-
idered  feasible  and  does  not  delay  the  PCI.  In  our  study,  we
id  not  use  ulnar  access.  Ipsilateral  ulnar  access  after  failure
f  attempted  radial  approach  is  not  usually  recommended
ecause  of  the  risk  of  radial  artery  occlusion  and  subsequent
and  ischaemia  in  the  event  of  ulnar  artery  puncture-related
omplications.  Ulnar  access  may  be  an  initial  choice  in  cases
f  difﬁcult  radial  anatomy,  such  as  laterally  positioned  or
eep  radial  access.  Although  not  used  in  our  study,  ultra-
ound  guidance  may  be  helpful  in  such  situations,  to  improve
he  success  rate  and  time  to  access  [30].  Based  on  these  con-
iderations  we  suggest  the  promotion  and  generalization  of
raining  in  radial  access,  and  the  concept  of  radial  artery  as
he  ﬁrst  approach  in  any  case.
tudy limitationshis  was  an  observational,  non-randomized,  relatively
mall-size  cohort  study,  and  several  known  or  unknown
ariables  associated  with  the  endpoints  may  have  not  been
nalysed.  Nevertheless,  we  tried  to  minimize  such  pitfallsV.  Roule  et  al.
y  the  use  of  adjusted  models,  improving  the  robustness  of
ur  analyses.  We  should  add  that  all  operators  were  highly
killed  in  the  radial  approach,  thereby  limiting  the  validity
f  our  results  in  lower-volume  radial  centres.
The  results  of  our  meta-analysis  should  be  tempered,  as
t  is  a  pooled  analysis  of  unadjusted  outcomes  from  obser-
ational  studies.  An  interaction  between  access  site  choice
nd  outcomes  remains  possible.
onclusion
he  transradial  approach  for  PCI  for  MI-related  CS  can  be
erformed  in  the  majority  of  patients;  it  is  associated  with
igniﬁcant  reductions  in  mortality  and  ischaemic  and  bleed-
ng  events,  leading  to  a  dramatic  net  clinical  beneﬁt.  The
ransradial  approach  may  be  recommended  in  such  criti-
ally  ill  patients  when  performed  by  trained  operators  in
xperienced  centres.
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